Sichun Yang

Has grant

Professor with Tenure

Case Western Reserve University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer

Open Date: 2021-04-01

Close Date: 2026-03-01

Grant: Close

Targeted disruption of estrogen receptor activation

Open Date: 2020-04-01

Close Date: 2022-03-31

Grant: Close

Multifaceted Modeling of Estrogen Receptor

Open Date: 2015-08-01

Close Date: 2020-07-31

Grant: Close

Multifaceted integration for estrogen receptor

Open Date: 2015-08-01

Close Date: 2025-08-31

Articles (12)

The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor downregulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor. Through computational screening and functional assays, we identified mitoxantrone (MTO), an FDA-approved topoisomerase II inhibitor, as a specific ligand for this DBD–LBD interface. Comprehensive biophysical, biochemical, and cellular analyses demonstrate that MTO binding induces distinct conformational changes in the ER, triggering rapid cytoplasmic redistribution and proteasomal degradation through mechanisms independent of its DNA damage activity. Critically, MTO effectively inhibits constitutively active ER mutants (Y537S and D538G) associated with endocrine therapy resistance, suppressing both wild-type and mutant ER-dependent gene expression and tumor growth more potently than fulvestrant in cellular and xenograft models. These findings establish the DBD–LBD interface as a druggable allosteric site that can overcome conventional resistance mechanisms, providing a new therapeutic paradigm for targeting nuclear receptor function through disruption of interdomain communication rather than hormone-binding competition.

Year:

2026

The conformational landscapes of intrinsically disordered proteins (IDPs) remain obscured by the ensemble averaging inherent to experimental observables. Here, we present Multi-replica Averaged Restraint Simulation (MARS), a data-driven modeling framework that reconstructs these landscapes by enforcing ensemble-averaged restraints across multiple replicas without imposing prior structural knowledge. Using the N-terminal domain of estrogen receptor alpha (ERα-NTD) as a model system, MARS simultaneously integrates small-angle X-ray scattering (SAXS) and six paramagnetic relaxation enhancement (PRE) profiles, comprising over 600 pairwise restraints, to generate ensembles that quantitatively fit all input structural restraints. The resulting ensemble is consistent with independent backbone relaxation measurements and reveals two major conformational states: a dominant extended state and a low-populated yet functionally relevant compact state whose structural features align with prior mutagenesis studies. Systematic benchmarking demonstrates that SAXS and PRE provide orthogonal global and local constraints, that each PRE profile contributes non-redundant structural information, and that multi-replica sampling is essential for preserving conformational heterogeneity. MARS offers a scalable framework for integrating orthogonal biophysical measurements to resolve both dominant and rare functional states in IDPs.

Year:

2026

The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor downregulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor. Through computational screening and functional assays, we identified mitoxantrone (MTO), an FDA-approved topoisomerase II inhibitor, as a specific ligand for this DBD–LBD interface. Comprehensive biophysical, biochemical, and cellular analyses demonstrate that MTO binding induces distinct conformational changes in the ER, triggering rapid cytoplasmic redistribution and proteasomal degradation through mechanisms independent of its DNA damage activity. Critically, MTO effectively inhibits constitutively active ER mutants (Y537S and D538G) associated with endocrine therapy resistance, suppressing both wild-type and mutant ER-dependent gene expression and tumor growth more potently than fulvestrant in cellular and xenograft models. These findings establish the DBD–LBD interface as a druggable allosteric site that can overcome conventional resistance mechanisms, providing a new therapeutic paradigm for targeting nuclear receptor function through disruption of interdomain communication rather than hormone-binding competition.

Year:

2026

Year:

2025

Treatment of estrogen receptor-positive (ER+) breast cancer is significantly hindered by endocrine resistance. We identified PML1 as a key therapeutic entity that can be targeted to overcome resistance. Endocrine-resistant breast cancer cells share three key characteristics: elevated PML1 protein levels, enhanced activity of PI3K, MAPK, or both signaling pathways, and reduced ER activity. We developed a PML1 gene signature that predicts poor prognosis and correlates strongly with PI3K, MAPK, and endocrine resistance gene signatures, as evident by cellular studies, scRNA-seq analysis, and spatial transcriptomics of endocrine therapy-treated tumors. This signature is present in endocrine-resistant breast cancer cells harboring the Y537S ER mutation. We consistently demonstrate high PML1 protein levels across cells resistant to various treatments, including 4-hydroxytamoxifen, fulvestrant, elacestrant, and CDK4/6 inhibitors. Furthermore, treatments with these therapeutic agents or knockdown of ESR1 mRNA also increase PML1 protein levels. Mechanistically, we show that ER inhibition through fulvestrant treatment activates PI3K and MAPK signaling, which enhance PML1 protein stability and synthesis. PML1 then drives a feedforward loop by stimulating the expression of cytokine and growth factor mRNAs, including CCL5 and HBEGF , further amplifying PI3K and MAPK signaling. Consequently, in endocrine-resistant cells, endocrine therapies, while inactivating ER, paradoxically reinforce this loop through increased PI3K/MAPK activation and PML1 protein accumulation, ultimately compromising therapeutic efficacy. Finally, we demonstrated that arsenic trioxide, an FDA-approved, PML-reducing drug, effectively disrupts this feedforward loop, offering a promising strategy for treating resistant metastatic breast cancer. STATEMENT OF SIGNIFICANCE Endocrine resistance remains a major obstacle in treating estrogen receptor-positive metastatic breast cancer. Our study identifies PML1 as a central mediator of this resistance, revealing how it maintains a self-reinforcing signaling network through PI3K and MAPK pathways by enhancing the production of cytokines and growth factors. The clinical significance of our findings is threefold: we establish PML1 as a biomarker for therapy resistance, demonstrate its mechanistic role in treatment failure, and show that FDA-approved arsenic trioxide can disrupt PML1-driven resistance. These insights provide a direct path to clinical translation, as combining arsenic trioxide with existing therapies could benefit patients with limited treatment options.

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Donald P. McDonnell

Duke University School of Medicine

UNITED STATES
View details

Wenwei Zheng

Arizona State University

UNITED STATES
View details

Alexandar Hansen

Research Scientist

Ohio State University

UNITED STATES
View details

Ruth A Keri

Case Western Reserve University

UNITED STATES
View details

Hung-Ying Kao

Full Professor

Case Western Reserve University School of Medicine

UNITED STATES
View details

Li-Sheng Geng

Professor of Physics

Beihang University

CHINA
View details

sandeep artham

Duke University

UNITED STATES
View details